

Award Number: W81XWH-18-1-0299

TITLE: Enhancing Outcomes of Radiation Therapy for Prostate Cancer

PRINCIPAL INVESTIGATOR: Sean E. McGuire MD PhD

CONTRACTING ORGANIZATION: Baylor College of Medicine, Houston, TX

REPORT DATE: December 2022

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> December 2022		<b>2. REPORT TYPE</b> Final		<b>3. DATES COVERED</b> 01Sep2018-31Aug2022	
<b>4. TITLE AND SUBTITLE</b>  Enhancing Outcomes of Radiation Therapy for Prostate Cancer				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> W81XWH-18-1-0299	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Sean McGuire MD PhD				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Baylor College of Medicine One Baylor Plaza Houston, Texas 77030				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> Prostate cancer (PCa) remains the most common malignancy and the second leading cause of cancer-related death for men in the United States. Every year tens of thousands of men in the US undergo treatment with of radiation therapy as a primary treatment for localized PCa. While results are often excellent, approximately one third will develop biochemical recurrence in 10 years and up to a third of men with biochemical recurrence will die of their disease, particularly men with higher stage and higher grade disease. In addition, thousands of men receive adjuvant radiation therapy following radical prostatectomy to try and prevent recurrence or for palliation of metastatic disease. Thus, improving outcomes of radiation therapy will have an immediate impact in the lives of men with PCa. In this proposal, we will determine the extent to which inhibition of two key prosurvival signaling pathways (RET and FGF receptors), alone and/or in combination, can enhance the effectiveness of radiation therapy.					
<b>15. SUBJECT TERMS</b> None listed.					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  Unclassified	<b>18. NUMBER OF PAGES</b>  12	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRDC
<b>a. REPORT</b>  Unclassified	<b>b. ABSTRACT</b>  Unclassified	<b>c. THIS PAGE</b>  Unclassified			<b>19b. TELEPHONE NUMBER (include area code)</b>

## Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	1
3. Accomplishments .....	1-6
4. Impact .....	6
5. Changes/problems.....	7
6. Products .....	7
7. Participants & Collaborating Organizations.....	7-8
8. References .....	9
9. Appendices .....	9

**1. INTRODUCTION:** Prostate cancer (PCa) remains the most common malignancy and the second leading cause of cancer-related death for men in the United States<sup>1</sup>. Every year tens of thousands of men in the US undergo treatment with radiation therapy as a primary treatment for localized PCa. While results are often excellent, approximately one third will develop biochemical recurrence in 10 years and up to a third of men with biochemical recurrence will die of their disease<sup>2</sup>, particularly men with higher stage and higher grade disease. In addition, thousands of men receive adjuvant radiation therapy following radical prostatectomy to try and prevent recurrence or for palliation of metastatic disease. Thus, improving outcomes of radiation therapy will have an immediate impact in the lives of men with PCa. In this proposal, we will determine the extent to which inhibition of two key prosurvival signaling pathways (RET and FGF receptors), alone and/or in combination, can enhance the effectiveness of radiation therapy.

COVID-19 has had a major negative impact on our on our research on this project. Like most research institutions, BCM shut down completely for many months. We proceeded with reopening but in stages with reduced staff hours. Not only was time lost for experimentation but we also had to freeze all cell lines before we left the lab such that they had to be regrown (which takes considerable time) and thus we actually went backwards. Animal experiments were also shut down and mouse numbers were severely restrained.

**2. KEYWORDS:** prostate cancer; nerve, RET, GDNF, GFR $\alpha$ 1, FGF, lenvatinib

**3. ACCOMPLISHMENTS:**

**A. Major Goals**


**Major Task 1: Obtain regulatory approvals (Months 1-4)**




All regulatory approvals have been obtained and maintained

**Major Task 2: Determine role of GDNF/ GFR $\alpha$ 1/RET signaling in resistance to radiation therapy (Months 4-36)**

**Subtask 1: In vitro studies of impact of RET signaling on radiation resistance (Months 4-24)**

We have carried out an extensive set of in vitro experiments to assess the impact of RET signaling on the response PCa cells to radiation. A subset of this data is presented below.





Figures 1 and 2 show that RET signaling induced by treatment with GDNF1 and GFR $\alpha$ 1 enhances cell viability after radiation treatment of LNCaP and 22RV1 PCa cells. Apoptosis was decreased in a similar experiment (data not shown). A similar impact on clonogenic survival after radiation was also observed (Figures 3 and 4)

**Subtask 2:** In vivo orthotopic experiments to determine if RET knockdown enhances radiation sensitivity (Months 8-36)

After obtaining all regulatory approvals and required trainings, we have initiated dose finding external beam radiation studies using the mouse orthotopic models, given that detailed studies of tumor survival after radiation published to date have not used orthotopic models. We have

therefore tested different doses of external beam radiation in mice bearing orthotopic tumors of LNCaP or 22RV1 cells. For LNCaP cells, a single dose at 2.5 Gy was sufficient to reduce luciferase activity by 46%. This is within our desired response range for wild-type LNCaP orthotopic tumors. For the 22RV1 tumors, two doses of 5Gy were required to reduce luciferase activity 42%, which is within our target range. Unfortunately further mouse experiments had to be aborted after initiation due to COVID-19 closure of the animal facilities.


**Subtask 3:** Correlative studies in human PCa to determine if expression of RET is associated with poor outcomes following radiation therapy (Months 4-28)

We have established a database of men treated for primary prostate cancer with external beam radiation at the MED VAMC from 1995 to 2009. A total of 1839 patients have been identified. Unfortunately for our study, outcomes were extremely good since many low risk PCa patients were radiated during this time limiting power to detect RET effects.


**Major Task 3: Evaluate role of FGFR signaling in promoting survival of radiated PCa cells (Months 4-36)**

**Subtask 1:** In vitro studies of impact of FGFR signaling on radiation resistance (Months 4-18)

Our initial studies sought to test the hypothesis that nerves enhance survival of prostate cancer cells after radiation. In order to test this hypothesis, we incubated dorsal root ganglia (DRG) with either LNCaP or 22RV1 prostate cancer cell lines and subjected them to mock irradiation, 3 Gy radiation or 6 Gy radiation treatments. The cells were then used for clonogenic assays and number of surviving clones counted. As can be seen in Figure 5, both for LNCaP and 22RV1 cells incubation with dorsal root ganglia significantly enhance survival after radiation. It should be noted that incubation with dorsal root ganglia also increased the number of clones and mock irradiated cells due to increased numbers of cells in response to growth factor secreted by the dorsal root ganglia. However the fold change in surviving cells was much higher in the irradiated cells, particularly in the cells treated with 6Gy (~1.4 versus 3-fold). Similar results were seen with PC3 cells (data not shown)




**Figure 5. Dorsal root ganglia enhance survival after radiation.** Dorsal root ganglia and incubated with matrigel and incubated with LNCaP or 22RV1 cells. Control plates contained matrigel only. Cells were then either mock irradiated or subjected to three or six Gy of external beam radiation. Cells were harvested used for clonogenic assays and number of clones with greater than 50 cells enumerated. The number of surviving colonies is presented as percent control mean at same radiation dose  $\pm$  SEM. \*p<0.05. \*\*p<0.01; \*\*\*p<0.001, Vs. matrigel only control at same level of radiation, t-test



To determine if secreted factors are, at least in part, responsible for the observed increase in survival we prepared conditioned media (CM) from DRGs and incubated this CM with LNCaP and 22RV1. Cells were then mock irradiated (0 Gy) or radiated with 3 or 6 Gy and clonogenic survival assessed. Control was CM without DRG. As shown in Figure 6, CM substantially increased clonogenic survival. Similar results were seen with PC3 cells (data not shown)

To determine if FGFR signaling via plays an important role in promoting radiation resistance due to nerves we cultured LNCaP cells with conditioned medium from dorsal root ganglia (DRG) for 24 hours, treated the cells with 0, 3 or 6 G of radiation and clonogenic survival assessed. As can be seen in Figure 7, AZD4547 treatment at 300 nM significantly decreased clonogenic survival




**Subtask 2:** In vivo orthotopic experiments to determine if FGFR inhibition enhances radiation sensitivity (12-36)

Unfortunately, these experiments were interrupted by COVID-19 and could not be completed.

**Major Task 4: Evaluate potential use of lenvatinib as a concurrent treatment to enhance radiation therapy (Months 4-36)**

**Subtask 1:** In vitro studies of impact of lenvatinib on radiation resistance (Months 4-24)

To determine if lenvatinib can inhibit radiation resistance induced by nerves via secreted factors, we cultured LNCaP cells with conditioned medium from dorsal root ganglia (DRG) for 24 hours, treated the cells with 0, 3 or 6 G of radiation in the absence or presence of lenvatinib and clonogenic survival assessed. As can be seen in Figure 8, lenvatinib treatment significantly decreased clonogenic survival in cells treated with 6G of radiation




**Subtask 2:** In vivo orthotopic experiments to determine if lenvatinib enhances radiation sensitivity (Months 14-36)

We were unable to complete these experiments due to COVID-19 closure of the animal facilities.


**Subtask 3:** Determination of signaling pathways impacted by lenvatinib in PCa (Months 4-14)

Examination of key signaling pathways activated by GDNF/GFR $\alpha$ 1 and inhibited by lenvatinib were carried out by Western blotting in LNCaP and 22RV1 cells as shown in Figures 9 and 10. Phosphorylation of AKT, p70-S6 kinase and S6 was significantly inhibited by lenvatinib and this was not effected by radiation treatment.



**Figure 9. Inhibition of key signaling pathways by lenvatinib.**

LNcaP cells were treated with GDNF/GFR $\alpha$ 1 in the presence of lenvatinib after radiation with 6 Gy or mock irradiation. Levels of phosphorylated p70-S6, AKT and S6 were assessed by Western blotting. Total p70-S6 kinase was also measured.  $\beta$ -actin was used as a loading control.



**Figure 10. Inhibition of key signaling pathways by lenvatinib.**

22RV1 cells were treated with GDNF/GFR $\alpha$ 1 in the presence of lenvatinib after radiation with 6 Gy or mock irradiation. Levels of phosphorylated p70-S6, AKT and S6 were assessed by Western blotting. Total p70-S6 kinase was also measured.  $\beta$ -actin was used as a loading control.

## **B. Training and Professional Development**

Junior investigators Kazunari Nohara Ph.D and Yun Zhu Ph.D to Baylor College of Medicine to worked on this project.

## **C. Dissemination to communities of interest**

Nothing to report

## **D. Plans for coming year**

We plan to write a manuscript presenting our results in the coming year.

## **4. IMPACT**

Our data to date supports the concept that RET and FGF signaling from nerves impacts cancer cell survival after radiation and can potentially be targeted in patients

## **5. CHANGES/PROBLEMS**

COVID-19 has significantly impacted our progress as described above

We have adapted the shielding used in the irradiator to make it suitable for irradiating orthotopic tumors while minimizing radiation of bone marrow and the gastrointestinal tract.

## **6. PRODUCTS**

None

## **7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

**Participants (see below)**

**Name:** Sean McGuire MD PhD

**Project Role:** Principal Investigator

**Nearest person month worked:** 2.4 calendar months

**Contribution to Project:** Overall project coordination and data analysis

**Funding Support:** No changes in funding support

**Name:** Michael Ittmann MD PhD

**Project Role:** Qualified Contributor

**Nearest person month worked:** 1.2 calendar months

**Contribution to Project:** Overall coordination and data analysis. He has also carried out extensive work on the patient database.

**Funding Support:** The following changes in funding support have occurred since this proposal was activated:

RO1CA227559 (Sreekumar/Palapattu)      05/01/2019-04/31/2024      0.12 calendar  
NIH

Metabolic Rewiring Promotes AA PCa by Regulating Stromal-Epithelial Interaction

The goal of this proposal is to examine metabolism in African American prostate cancer Dr. Ittmann is providing pathology support. No overlap.

PC181023 (Lotan)      9/1/2019-8/31/2022      0.24 calendar  
DOD Prostate Cancer Research Program HDA

Epigenomic Landscape of Primary Prostate Cancer in African American Men

The goal of this proposal is to examine the epigenetic alterations in African American prostate cancer. We will provide samples for a validation cohort. No overlap.

2U54MD007597-31 (Kwabi-Addo)      08/01/19-07/31/24      0.6 calendar

NIH      (BCM directs)

Epigenetic regulated genes in African American Prostate Cancer Patients

The goal is to understand the biological basis for the more aggressive clinical behavior of prostate cancer in African American men and to begin to develop predictive tools to help manage prostate cancer in African American men. No overlap.

W81XWH-19-1-0410 (Frigo)      7/15/2019-7/14/2022      0.6 calendar DOD  
Prostate Cancer Program      (salary support only)

Therapeutic Targeting of the Glutamine Transporter SLC1A5 in Advanced Prostate Cancer To rigorously evaluate SLC1A5's role in prostate cancer metabolism and test whether SLC1A5 represents a viable therapeutic target. No overlap.

**Name:** Shu Feng, MD PhD

**Project Role:** Co-investigator

**Nearest person month worked:** 12 calendar months

**Contribution to Project:** Dr Feng has carried out much of the in vitro work described above

**Funding Support:** No changes in funding support

**Name:** Jianghua Wang MD

**Project Role:** Co-investigator

**Nearest person month worked:** 1.2 calendar months

**Contribution to Project:** Dr. Wang has assisted with in vitro and in vivo experiments. **Funding**

**Support:** No changes in funding support

8

### **Collaborating organizations**

None. This is an internal collaboration within Baylor College of Medicine

## **8. REFERENCES**

1. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017, *CA Cancer J Clin* 2017, 67:7-30
2. Bruce JY, Lang JM, McNeel DG, Liu G: Current controversies in the management of biochemical failure in prostate cancer, *Clin Adv Hematol Oncol* 2012, 10:716-722

## **C. Appendices**

None